Talimogene laherparepvec plus pembrolizumab achieved response in 62% of patients with melanoma.

中文翻译：

---

Talimogene Laherparepvec增强了PD-1阻断的功效

Talimogene laherparepvec和pembrolizumab在62％的黑色素瘤患者中获得了缓解。